Aims: Mesenteric tumour deposits frequently occur in small-intestine neuroendocrine tumours. In many instances, these mesenteric tumour deposits are surrounded by a dense fibrotic stroma and have associated lymphoplasmacytic inflammation. The aim of this study was to examine whether mesenteric tumour deposits in patients with small-intestine NETs neuroendocrine tumours show histological and immunophenotypic overlap with IgG4-related sclerosing mesenteritis. Methods and results: Sixty-six mesenteric tumour deposits from 66 patients with small-intestine neuroendocrine tumours with blocks available for further studies were identified from our archives. Cases were assessed for clinicopathological features and the presence of IgG4-positive and IgG-positive plasma cells by immunohistochemistry. Ratios of IgG4-positive to IgGpositive plasma cells were calculated. Seventeen mesenteric tumour deposits (26%) showed >40 IgG4-positive plasma cells per high-power field, and the majority of cases (68%) showed at least some staining of IgG4-positive plasma cells. Mesenteric tumour deposits with >20 IgG4-positive plasma cells per high-power field tended to be larger (25.9 AE 13.0 mm versus 18.6 AE 15.8 mm; P = 0.07), and had more IgG-positive plasma cells (88 AE 24 versus 36 AE 37; P < 0.01) and a higher IgG4-positive/IgG-positive plasma cell ratio (0.66 AE 0.18 versus 0.17 AE 0.25; P < 0.01). All but one mesenteric tumour deposit with >20 IgG4-positve plasma cells had a ratio of >40%. Conclusions: IgG4 expression is frequent in mesenteric tumour deposits from small-intestine neuroendocrine tumours. Undersampling of tumour on biopsies of mesenteric tumour deposits could potentially cause diagnostic confusion with IgG4-related sclerosing mesenteritis.
Introduction
Small-intestine neuroendocrine tumours (NETs) are the most commonly encountered malignant neoplasms of the small intestine, with an incidence of five per 100 000. 1, 2 They are frequently associated with lymph node metastasis and mesenteric tumour deposits (MTDs), both of which alter the overall stage in the 8th edition of the American Joint Committee on Cancer (AJCC) staging system for small-intestine NETs. [3] [4] [5] MTDs are defined as discrete but irregular mesenteric tumour nodules discontinuous from the primary neoplasm; they are associated with frequent liver metastasis and a poor prognosis. 5, 6 In addition, MTDs are frequently associated with dense fibrosis, which can lead to entrapment of adjacent large mesenteric vessels and nerves. Because of this dense fibrotic response to tumour, MTDs can radiographically simulate IgG4-related sclerosing mesenteritis, complicating diagnosis by imaging and necessitating tissue diagnosis. 7 IgG4-related sclerosing mesenteritis is characterised by fibrosis, lymphoplasmacytic inflammation, and obliterative thrombophlebitis with prominent IgG4-positive plasma cells (PCs). 8 Microscopically, the sclerosing fibrotic stromal response associated with MTDs is often accompanied by similar adjacent foci of lymphoplasmacytic inflammation. If these features are present on core biopsy when tumour cells are not sampled, MTDs can histologically mimic sclerosing mesenteritis. This study examined whether MTDs in patients with small-intestine NETs showed histological and immunophenotypic overlap with IgG4-related sclerosing mesenteritis.
Materials and methods
Seventy patients with MTD(s) arising in small-intestine NET were identified from our pathology archives between 1 January 1996 and 1 July 2017; 66 of these had at least one MTD block available for immunohistochemical (IHC) staining. MTDs were defined as discrete tumour nodules within mesenteric soft tissues with an irregular growth pattern. 5, 6 Lesions resulting from direct contiguous spread by the primary lesion or extranodal extension were excluded. Patient electronic medical records were reviewed for demographic information, including age, sex, and clinical history. Pathology reports and slides of the 66 cases were reviewed, and AJCC tumour stage, tumour grade and MTD size were all recorded. This retrospective study was approved by Vanderbilt Institutional Review Board (IRB no. 101735; 1 May 2014 to 13 September 2018).
For IHC labelling, 4-lm unstained tumour sections from formalin-fixed paraffin-embedded tissue were deparaffinised with routine methods. Antigen retrieval was performed as follows. Slides were heated in a pH 9.0 EDTA buffer at 97°C for 20 min in a pressure cooker, and this was followed by 10 min of cooling to room temperature. All slides were then quenched with 0.02% H 2 Immunohistochemical labelling for IgG4 and IgG was performed on one MTD from each of the 66 cases; for cases with multiple MTDs, the staining was performed on the largest. IgG-positive and IgG4-positive PCs were quantified by finding the highest concentration of positive PCs in one high-power field (HPF) in areas of sclerotic stroma adjacent to tumour. The ratio of IgG4-positive to IgG-positive PCs was obtained by dividing the number of IgG4-positive PCs by the number of IgG-positive PCs in one selected HPF. Cases were divided into two groups based on the number of IgG4-positive PCs per HPF: group 1 had 0-20 per HPF, and group 2 had >20 per HPF. The Ki67 index was available for all cases, and was used to grade each primary tumour according to the 2010 World Health Organization (WHO) criteria. 9 The data were analysed with GRAPHPAD PRISM Version 5.01 (GraphPad Software, La Jolla, CA, USA). Fisher's exact test and Student's t-test were used to compare clinicopathological variables and IHC results between two groups. A P-value of <0.05 was considered to be statistically significant.
Results
Of the 66 patients, 34 were male and 32 were female; their mean age was 59 years (range: 19-83 years). Of the primary small-intestine NETs, 51 were WHO grade 1 and 15 were WHO grade 2 ( Table 1) . Twenty-seven cases presented with AJCC stage II-III tumour (one stage II and 26 stage III), and 39 with stage IV tumour.
Most patients had one MTD, whereas some (26/66, 40%) had more than one. The median MTD size was 18 mm, ranging from 2 to 70 mm. All 66 MTDs showed fibrotic stroma, which was often more prominent at the periphery of the MTDs and was frequently associated with lymphoplasmacytic inflammation ( Figure 1A ). Significant lymphoplasmacytic inflammation, defined as foci of inflammation easily identified at low power, was seen in 46 (70%) MTDs ( Figure 1B) . No obliterative thrombophlebitis was seen in any of the cases. The fibrosis associated with MTDs was hypocellular and frequently associated with prominent hyalinisation (Figure 2A) . Foci of calcification often developed in large hyalinised areas. At the periphery, focal fibrosis in a subtle storiform pattern ( Figure 2B ) was observed in 18 of 66 (27%) cases, and was frequently associated with lymphoplasmacytic inflammation and/or fat necrosis.
Twenty of 66 MTDs (30%) showed >20 IgG4-positive PCs per HPF (group 2), including 17 (26%) with >40 per HPF ( Figure 1C ) and three (4%) with 21-40 per HPF. Forty-six (70%) MTDs had ≤20 IgG4-positive PCs per HPF (group 1); among them, 21 (32%) had no IgG4-positive PCs, and 25 (38%) had 1-20 per HPF. Overall, more than two-thirds of MTDs showed at least some staining of IgG4-positive PCs.
There were no statistical differences in age, sex, WHO tumour grade, MTD size or AJCC tumour stage between group 1 and group 2 (Table 1) . However, MTDs with >20 IgG4-positive PCs per HPF tended to be larger than those with ≤20 IgG4-positive PCs per HPF (P = 0.07). In addition, MTDs with >20 IgG4-positive PCs per HPF were more often AJCC stage IV, although this was not statistically significant (P = 0.17).
IgG staining performed on all MTDs ( Figure 1D ) showed more IgG-positive PCs in group 2 (with >20 IgG4-positive PCs per HPF) than in group 1 (P < 0.01; Table 1 ). The number of IgG-positive PCs ranged from 0 to 78 per HPF in group 1 and from 60 to 132 per HPF in group 2. The IgG4-positive/ IgG-positive PC ratio was also higher in group 2 (P < 0.001; Table 1 ). Ten of 46 (22%) MTDs in group 1 had a ratio of >0.2, whereas all MTDs in group 2 had a ratio of >0.2, and all but one had a ratio of >0.4.
Discussion
Mesenteric tumour deposits frequently occur in smallintestine NETs. They are discrete mesenteric tumour nodules with irregular contours. Histologically, most MTDs are associated with extensive fibrosis constricting entrapped large mesenteric vessels, and consequently resulting in small-bowel ischaemia or infarct. We have shown that up to 60% of small-intestine NETs present with MTDs. 5 Furthermore, their presence is associated with several poor prognostic factors, including high T-category stage at presentation, increased propensity for lymphovascular invasion, and lymph node and liver metastasis. When present, they are usually larger than primary tumours. Sometimes MTDs may be the only finding on imaging studies, and distinction between other processes such as lymphoma and other mesenteric diseases can be difficult by imaging alone. 7, 10 IgG4-related disease is a fibroinflammatory tumefactive process characterised by a dense lymphoplasmacytic infiltrate enriched with IgG4-positive PCs, storiform fibrosis, and frequent elevations of serum IgG4. 11 It was first recognised in patients with autoimmune pancreatitis who manifested with extrapancreatic symptoms. 12 Since then, IgG4-related disease has been described in many different organ systems, and the diagnostic criteria have been better defined. 13, 14 The three major histopathological features noted are dense lymphoplasmacytic inflammation, fibrosis (at least focally storiform), and obliterative thrombophlebitis. The diagnosis can be confidently made when two of these three features are present. IgG and IgG4 IHC stains can also assist in diagnosis by allowing quantification of the number of IgG4-positive PCs per HPF and the overall IgG4-positive/IgG-positive PC ratio. It has been suggested that >30 IgG4-positive PCs per HPF and/or an IgG4-positive/IgG-positive PC ratio of 40% can be used to assist in diagnosis; however, these numbers were mainly generated from one or a small number of studies per site. 13, 14 Therefore, minimum IgG4 PC counts for the diagnosis at different sites are still questionable at present. The diagnosis can be difficult in some instances, and IgG4-related disease has been known to mimic a number of other diagnoses, including granulomatosis with polyangiitis and Rosai-Dorfman disease. 15 Mesenteric tumour deposits seen in small-intestine NETs can be impressive mimics of IgG4-related sclerosing mesenteritis clinically and radiographically. Furthermore, the adjacent fibrosis and lymphoplasmacytic inflammation can cause histological confusion in the absence of sampled tumour cells. Our study demonstrates that, in addition to these histological findings, significant numbers of IgG4-positive PCs Some clinical and radiographic features may help to distinguish MTD from sclerosing mesenteritis. Approximately one-third of patients with sclerosing mesenteritis have a history of abdominal surgery or abdominal trauma. 16, 17 Patients with sclerosing mesenteritis can be asymptomatic, but common signs/symptoms include abdominal pain, palpable abdominal mass, fever, weight loss, and small-bowel obstruction. Signs and symptoms of small-bowel obstruction/ischaemia may also occur in smallintestine NET patients when large MTDs cause kinking of the bowel and encasing of large mesenteric vessels. Additionally, patients with MTDs frequently have liver metastasis, 5, 6 and they can develop carcinoid syndrome when there are extensive liver metastases. Radiographically, both entities appear as a soft-tissue mesenteric mass with radiating fibrotic bands in a stellate pattern; however, MTDs tend to encase and invade mesenteric vessels, whereas sclerosing mesenteritis often spares mesenteric fat immediately surrounding vessels, producing a 'fat ring sign'. 17 The presence of one or more primary tumours in the small intestine and hypervascular liver masses favour MTDs arising in smallintestine NET.
In summary, MTDs in small-intestine NETs can have extensive areas of fibrosis and chronic inflammation surrounding the tumour, which can cause undersampling of the tumour on core biopsy. In addition, IgG4 expression is frequent in MTDs. It is important to be aware of this potential pitfall when dealing with a biopsy of a mesenteric mass.
